Targeting targeted agents: open issues for clinical trial design

  title={Targeting targeted agents: open issues for clinical trial design},
  author={Emilio Bria and Massimo Di Maio and Paolo Carlini and Federica Cuppone and Diana Giannarelli and Francesco Cognetti and Michele Milella},
  journal={Journal of Experimental & Clinical Cancer Research : CR},
  pages={66 - 66}
Molecularly targeted agents for the treatment of solid tumors had entered the market in the last 5 years, with a great impact upon both the scientific community and the society. Many randomized phase III trials conducted in recent years with new targeted agents, despite previous data coming from preclinical research and from phase II trials were often promising, have produced disappointingly negative results. Some other trials have actually met their primary endpoint, demonstrating a… CONTINUE READING